• About Us
  • Contact Us
  • Photo Gallery
  • Privacy Policy
  • Terms of Use
  • Citi TV
Friday, June 9, 2023
Citinewsroom - Comprehensive News in Ghana
  • Home
  • News
  • Business
  • Sports
  • Showbiz
  • Coronavirus
  • Infographics
  • Livestream
  • Videos
No Result
View All Result
Citinewsroom - Comprehensive News in Ghana
  • Home
  • News
  • Business
  • Sports
  • Showbiz
  • Coronavirus
  • Infographics
  • Livestream
  • Videos
No Result
View All Result
Citinewsroom - Comprehensive News in Ghana
No Result
View All Result

Clinical trial for COVID-19 herbal treatment to last for two months – FDA

byZoe Abu-Baidoo Addo
February 1, 2021
Reading Time: 2 mins read
the Food and Drugs Authority FDA
ShareShareShareShare

The Food and Drugs Authority (FDA) expects the clinical trial of the malaria herbal treatment known as Nibima for the treatment of COVID-19 to last two months.

The head of Clinical Trials Department at the FDA, Yvonne Adu Boahene, explained that “the trial duration is for just two months, but medication is taken for seven days of treatment.”

The clinical trials of the repurposed herbal medication will be done at two sites in the Ashanti Region at the Komfo Anokye Teaching Hospital and Kumasi South Hospital.

Mrs. Boahene told Citi News “the FDA is happy about this and is excited, and I think it is a good step for the FDA and Ghana as a whole.”

According to the FDA, after a detailed assessment of the application by researchers from the school of public health at the Kwame Nkrumah University of Science and Technology, it gave the requisite authoriSation for the conduct of the trial.

The researchers in September 2020, submitted the clinical trial application to assess the safety and efficacy of the medicine as a potential treatment for COVID-19 which subsequently received approval in January 2021.

The Centre for Plant Medicine Research (CPMR) had previously recommended 17 herbal medications to the government as a supplementary treatment for the novel coronavirus.

Nine of the 17 recommended herbal remedies were registered products whilst eight others have not yet been approved by the Food and Drugs Authority (FDA).

One of them, Immuno-19, however, contained Cryptolepis Sanguinolenta, which are the Nibima ingredients.

Those recommendations were based on the biological activities of the medicinal plants used in the formulation of the remedies, the status of the product as being FDA registered, the traditional uses of the plant constituents and some chronic toxicity studies and anecdotal clinical data available on the product.

ShareTweetSendSend
Previous Post

Another police officer allegedly dies by suicide in Accra

Next Post

Udeotuk Wills admits knowing two of murdered kidnapped Takoradi girls

Related Posts

Top Stories

Supreme Court strikes out law that allowed govt to impose restrictions during Covid-19

May 31, 2023
General

Players in hospitality sector receive training to bounce back from impact of COVID-19

May 28, 2023

Scrap COVID-19 tax you imposed on Ghanaians – CSO to govt

May 24, 2023
Top Stories

Ghana lifts COVID-19 restrictions at all entry points

May 20, 2023
Top Stories

Don’t let your guards down, COVID-19 still around – WHO warns

May 9, 2023
Top Stories

We won’t let our guard down – Govt on end to COVID-19 emergency

May 6, 2023
Next Post

Udeotuk Wills admits knowing two of murdered kidnapped Takoradi girls

TOP STORIES

We’ll complete Kumawu roads to ‘shame doubting Thomases’- Amoako-Attah

June 8, 2023

Govt issues one-month ultimatum for merchant subscribers to register SIMs

June 8, 2023

#CitiBusinessFestival: Go digital to increase customer reach – Businesses told

June 8, 2023
Load More
ADVERTISEMENT
Citinewsroom – Comprehensive News in Ghana

CitiNewsroom.com is Ghana's leading news website that delivers high quality innovative, alternative news that challenges the status quo.

Archives

Download App

Download

Download

  • About Us
  • Contact Us
  • Photo Gallery
  • Privacy Policy
  • Terms of Use
  • Citi TV

© 2023 All Rights Reserved Citi Newsroom.

No Result
View All Result
  • Home
  • News
  • Business
  • Sports
  • Showbiz
  • Coronavirus
  • Infographics
  • Livestream
  • Videos

© 2023 All Rights Reserved Citi Newsroom.

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept All”, you consent to the use of ALL the cookies. However, you may visit "Cookie Settings" to provide a controlled consent.
Cookie SettingsAccept All
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
SAVE & ACCEPT